Of clinical relevance, we found that ovarian cancer patients bearing a low level of MIR1305 and high expression of DIRAS3 have a longer overall survival compared to patients in which the CNV of MIR1305 was unaltered. This evidence concerns the gene MIR1305 and ovarian cancer.